Dae Gon Ha
Stock Analyst at Stifel
(2.65)
# 1,335
Out of 4,413 analysts
34
Total ratings
30%
Success rate
1.34%
Average return
Main Sectors:
Top Industries:
21 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Initiates: Buy | $48 | $25.72 | +86.63% | 1 | Apr 17, 2024 | |
| KRYS Krystal Biotech | Reiterates: Buy | $178 → $204 | $159.67 | +27.76% | 3 | Apr 16, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $6.00 | +566.67% | 3 | Apr 3, 2024 | |
| SLNO Soleno Therapeutics | Initiates: Buy | $63 | $47.54 | +32.52% | 1 | Jan 23, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $9 → $17 | $5.47 | +210.79% | 2 | Sep 29, 2023 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $22.53 | +113.05% | 4 | Sep 13, 2023 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $11 | $7.33 | +50.07% | 3 | Aug 22, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $5.27 | +241.56% | 1 | Apr 18, 2023 | |
| EQ Equillium | Maintains: Buy | $12 → $7 | $1.46 | +379.45% | 1 | Mar 24, 2023 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $176 → $142 | $43.30 | +227.94% | 1 | Jul 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $23 → $25 | $41.43 | -39.66% | 1 | Jun 17, 2022 | |
| FOLD Amicus Therapeutics | Upgrades: Buy | n/a | $10.43 | - | 3 | Nov 15, 2021 | |
| NTLA Intellia Therapeutics | Initiates: Buy | n/a | $22.50 | - | 1 | Sep 24, 2021 | |
| SRZN Surrozen | Initiates: Buy | $285 | $9.83 | +2,800.76% | 1 | Sep 7, 2021 | |
| PRQR ProQR Therapeutics | Initiates: Buy | n/a | $2.00 | - | 1 | May 3, 2021 | |
| AVRO AVROBIO | Initiates: Hold | n/a | $1.22 | - | 1 | Mar 2, 2021 | |
| CRBP Corbus Pharmaceuticals Holdings | Downgrades: Neutral | n/a | $37.25 | - | 2 | Sep 8, 2020 | |
| APLS Apellis Pharmaceuticals | Initiates: Neutral | n/a | $46.05 | - | 1 | Jun 17, 2020 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Neutral | n/a | $4.57 | - | 1 | Jun 17, 2020 | |
| IFRX InflaRx | Initiates: Buy | n/a | $1.41 | - | 1 | Jun 17, 2020 | |
| DBVT DBV Technologies | Maintains: Outperform | n/a | $0.69 | - | 1 | Oct 23, 2017 |
Mirum Pharmaceuticals
Apr 17, 2024
Initiates: Buy
Price Target: $48
Current: $25.72
Upside: +86.63%
Krystal Biotech
Apr 16, 2024
Reiterates: Buy
Price Target: $178 → $204
Current: $159.67
Upside: +27.76%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $6.00
Upside: +566.67%
Soleno Therapeutics
Jan 23, 2024
Initiates: Buy
Price Target: $63
Current: $47.54
Upside: +32.52%
Editas Medicine
Sep 29, 2023
Upgrades: Buy
Price Target: $9 → $17
Current: $5.47
Upside: +210.79%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $22.53
Upside: +113.05%
Fulcrum Therapeutics
Aug 22, 2023
Upgrades: Buy
Price Target: $11
Current: $7.33
Upside: +50.07%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $5.27
Upside: +241.56%
Equillium
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $1.46
Upside: +379.45%
Ultragenyx Pharmaceutical
Jul 1, 2022
Maintains: Buy
Price Target: $176 → $142
Current: $43.30
Upside: +227.94%
Rhythm Pharmaceuticals
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $41.43
Upside: -39.66%
Amicus Therapeutics
Nov 15, 2021
Upgrades: Buy
Price Target: n/a
Current: $10.43
Upside: -
Intellia Therapeutics
Sep 24, 2021
Initiates: Buy
Price Target: n/a
Current: $22.50
Upside: -
Surrozen
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $9.83
Upside: +2,800.76%
ProQR Therapeutics
May 3, 2021
Initiates: Buy
Price Target: n/a
Current: $2.00
Upside: -
AVROBIO
Mar 2, 2021
Initiates: Hold
Price Target: n/a
Current: $1.22
Upside: -
Corbus Pharmaceuticals Holdings
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $37.25
Upside: -
Apellis Pharmaceuticals
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $46.05
Upside: -
BioCryst Pharmaceuticals
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $4.57
Upside: -
InflaRx
Jun 17, 2020
Initiates: Buy
Price Target: n/a
Current: $1.41
Upside: -
DBV Technologies
Oct 23, 2017
Maintains: Outperform
Price Target: n/a
Current: $0.69
Upside: -